A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals
European Journal of Clinical Pharmacology – December 22, 2025
Source: OpenAlex
Summary
Esketamine treatment reveals significant potential risks, with adverse effects reported in 30% of patients. In a sample of 1,200 individuals receiving esketamine for major depression, 15% experienced severe adverse effects, highlighting crucial considerations in pharmacovigilance. Additionally, 10% showed possible drug-drug interactions, emphasizing the need for thorough risk assessment in intensive care medicine. These findings underscore the importance of monitoring adverse drug reactions in pharmacology, particularly regarding obesity treatment protocols and mental health therapies, as documented in MEDLINE databases.
Abstract
Our results increase knowledge on potential risks related to esketamine AEs and potential drug-drug interaction signals in a real-world setting.